Smith+Nephew Cuts Outlook, Ends J&J Merger Talks
The medical device maker lowered its full-year revenue and profit forecasts after its orthopaedics unit showed weak growth.
Updated on Nov. 4, 2026 in Healthcare
Smith+Nephew cut its full-year revenue and profit forecasts and confirmed that merger talks with Johnson & Johnson's orthopaedics unit have ended. The company said it approached Johnson & Johnson earlier this year about a potential merger, and the talks collapsed over disagreements on who would run the enlarged group.
Why it matters
The outlook cut reflects an expected slowdown in the Orthopaedics unit that is projected to persist through the final quarter. Smith+Nephew said it will continue to explore strategic options for the business.
Smith+Nephew lowered both its full-year revenue and profit forecasts, with the cut tied to weak growth in its Orthopaedics unit. The company did not disclose the size of the revised figures or why the Johnson & Johnson talks collapsed.
The players
Smith+Nephew
A British multinational medical technology company that designs and manufactures orthopaedics, sports medicine, and wound management products.
Johnson & Johnson
A major American multinational healthcare company whose orthopaedics unit was the subject of the proposed merger.
The details
Smith+Nephew confirmed on Wednesday that it approached Johnson & Johnson earlier this year about merging its orthopaedics arm, a move Reuters first reported in October. The company has been grappling with weak growth in the unit, and it expects that slowdown to persist through the final quarter.
Timeline
Earlier in 2026: Smith+Nephew approached Johnson & Johnson about a merger.
October 2026: Reuters reported the merger talks.
November 4, 2026: Smith+Nephew confirmed the talks ended and cut its outlook.
Market Landscape
The collapsed talks extend a wave of orthopaedics consolidation among large device makers seeking scale in a competitive segment. The disagreement over leadership of a combined group highlights why such deals have repeatedly stalled despite their strategic appeal.
Patients and hospitals relying on Smith+Nephew orthopaedic products may see the company's strategic direction shift as it explores further options. Investors and procurement teams should watch the final-quarter results for confirmation of the Orthopaedics slowdown.
The takeaway
Strategic mergers in medical devices often hinge on leadership structure as much as on financial logic. Watching how Smith+Nephew deploys its next strategic move will show whether it can restore growth in its Orthopaedics unit.
Further reading
For broader context on the industry, see Healthcare coverage on Wisevoter.
